Semaglutide Linked to 50% Lower Addiction Mortality in Major Veterans Study

A pair of large-scale studies on U.S. veterans has produced striking evidence that semaglutide—the active ingredient in Ozempic and Wegovy—may substantially reduce the risks associated with addiction and mental illness. The findings, published in recent weeks, suggest that the blockbuster medications originally developed for diabetes and weight management could have far-reaching implications for how clinicians approach substance use disorders and psychiatric conditions.

The first study, analyzing outcomes for more than 600,000 veterans with diabetes, found that those who initiated GLP-1 treatment had a 14% lower overall risk of developing a new substance use disorder compared to patients starting on a different class of diabetes medication. More dramatically, among veterans who already had substance use disorders, GLP-1 treatment was associated with a 50% reduction in mortality risk.

Breaking Down the Numbers

The magnitude of the observed effects has captured attention across the medical community. For patients with existing substance use disorders, the study documented:

• 31% fewer emergency department visits related to substance use
• 26% fewer hospital admissions
• 39% fewer overdoses
• 25% reduction in suicidal thoughts or attempts
• 50% fewer deaths from any cause

These figures emerge from a comparison between veterans who started GLP-1 drugs and those who began taking SGLT2 inhibitors, another active diabetes treatment. The choice of comparator matters: rather than comparing treated patients to untreated controls, the researchers compared two groups receiving contemporary medical care, suggesting the benefits are specific to GLP-1 mechanisms rather than general improvements in health management.

A Separate Psychiatric Signal

Complementing the addiction findings, a second large observational study found that semaglutide use was associated with a 42% lower risk of worsening mental illness. The analysis tracked outcomes including depression, anxiety, and self-harm behaviors, finding that the protective effect extended across multiple psychiatric domains.

The pattern suggests semaglutide may influence brain pathways beyond those controlling appetite and metabolism. Researchers have proposed several mechanisms: the drug's effects on reward signaling, its potential to modulate craving responses, and its influence on stress processing systems. Addiction, depression, and metabolic disease frequently co-occur in the same patients, and a medication that addresses multiple pathways simultaneously could represent a significant therapeutic advance.

Not all GLP-1 drugs showed equivalent effects. Liraglutide demonstrated an 18% reduction in mental illness risk—substantial, but smaller than semaglutide's 42%. Other medications in the class, including exenatide and dulaglutide, did not show comparable benefits in the summarized reports. Whether these differences reflect genuine variation in central nervous system penetration, dosing patterns, or patient selection factors remains an active research question.

From Weight Loss to Addiction Medicine

The findings add to a growing body of evidence that GLP-1 receptor agonists may have therapeutic applications well beyond their approved indications. Animal studies have long suggested these drugs affect dopamine signaling and reward pathways. Human observational studies have documented reduced alcohol consumption, decreased smoking rates, and diminished compulsive behaviors among patients taking the medications for diabetes or obesity.

What distinguishes the new veterans studies is their scale and their clinical specificity. With over 600,000 participants and hard outcome measures—including mortality, overdose, and hospitalization—the data carry weight that smaller trials cannot match. The 50% mortality reduction, in particular, represents an effect size rarely seen in addiction research.

Important Caveats

Both studies were observational, meaning they demonstrate association rather than causation. Veterans who were prescribed GLP-1 drugs may have differed from the comparison group in ways the researchers could not fully measure—differences in healthcare engagement, socioeconomic status, or underlying health status that could influence outcomes independent of the medication itself.

The study authors explicitly acknowledged this limitation, calling for randomized controlled trials to establish whether the observed benefits are genuinely attributable to the medications. Such trials are now underway, with several academic centers investigating GLP-1 drugs specifically for alcohol use disorder, opioid use disorder, and smoking cessation.

Clinical Implications

For clinicians, the findings raise practical questions about patient selection and monitoring. Patients with diabetes or obesity who also struggle with alcohol use disorder or other addictions may be particularly good candidates for GLP-1 therapy, though the medications are not yet approved specifically for addiction treatment. Conversely, addiction specialists may find themselves fielding questions from patients who have heard about the studies and want to know whether semaglutide could help their recovery.

The research also highlights the interconnected nature of metabolic and psychiatric health. Patients presenting with obesity or diabetes often carry unrecognized addiction or mental health burdens. The possibility that a single medication class could address multiple conditions simultaneously challenges the siloed approach that often characterizes specialty care.

As the randomized trials progress, the veterans data provide a compelling signal that GLP-1 drugs may have a role in the addiction treatment toolkit. For a field that has seen few pharmacological advances in recent decades, the prospect of repurposing an already-approved, widely available medication represents a potentially significant opportunity.